Blog

Target lncRNA gene for esophageal squamous-cell cancer found

lncRNA

Korean researchers said they have found a new gene that controls the development of esophageal squamous cell carcinoma (ESCC), intractable cancer in the esophagus. The finding is likely to allow researchers to develop a diagnostic platform and a treatment agent for esophagus cancer. The research team, led by Professor Lee Sang-kil at Yonsei Institute of Gastroenterology at Yonsei University College ...

Read More »

Long non-coding RNA implicated in triple negative breast cancer

lncRNA

A slice of RNA that doesn’t code for a protein manages to stifle tumor-suppressing genes and wreck the cellular mechanism that flags cancer cells for destruction by the immune system. Writing this month in Nature Immunology, a team led by scientists at MD Anderson shows that the long, non-coding RNA (lncRNA) called LINK-A is a potential therapeutic target for triple negative breast ...

Read More »

Abivax Treats First Patient in Phase 2a Rheumatoid Arthritis Clinical Trial of ABX464

lncRNA

Abivax, a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announced today that the first patient was dosed in study ABX464-301, a phase 2a clinical trial of ABX464 to treat patients with moderate to severe active rheumatoid arthritis (RA). The trial has been fully approved in four countries (France, Poland, ...

Read More »